Featured Publications

Guidelines for the use of immunotherapy to treat patients with bladder carcinoma were recently published as part of the Society for Immunotherapy of Cancer’s (SITC) Cancer Immunotherapy Guidelines series. It joins guidelines for prostate carcinoma, hematologic malignances, and renal cell carcinoma as a crucial resource developed through multidisciplinary collaboration between academic researchers and physicians, nurses, patients, and patients advocates from throughout the U.S.

The SITC Combination Immunotherapy Task Force white paper published earlier this year, entitled “Combination immunotherapy: a road map” (Ott et al.), aims to identify the most promising prospects for combination therapy and address challenges associated with combinatorial approaches. Building on previous work on combination immunotherapy, this article is the first to address the use of mouse models, safety considerations in early clinical testing, the need for innovative early phase clinical trial designs, and appropriate safety and efficacy endpoints for early phase clinical trials, all in the specific setting of combination immunotherapy.

Article series

Immune monitoring technology primers
Reviewed by the members of the SITC Immune Biomarkers Task Force, these brief primers highlight important aspects of both standardized and novel technologies available in clinical trial settings.

SITC Cancer immunotherapy guidelines
Developed by experts in the treatment of specific types of cancer, each consensus statement provides key indicators to help practicing oncologists determine when and how to best use immunotherapy to treat their patients.​​​​​​​

Articles

August Articles

CASE REPORT

New Content Item
Predictive role of PD-L1 expression in the response of renal Medullary carcinoma to PD-1 inhibition

Renal medullary carcinoma is one of the rarest malignancies arising from the kidney. Despite various aggressive therapeutic regimens, mortality remains significantly…

Quaovi Sodji, Kandy Klein, Kavuri Sravan and Jigarkumar Parikh

CASE REPORT

New Content Item

Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series

Monoclonal antibodies targeting the PD-1/PD-L1 axis have gained increasing attention across many solid tumors and hematologic malignancies due to their efficacy…

Dylan J Martini, Aly-Khan A Lalani, Dominick Bossé, John A Steinharter, Lauren C Harshman, F Stephen Hodi, Patrick A Ott and Toni K Choueiri

POSITION ARTICLE AND GUIDELINES

New Content Item
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma

The standard of care for most patients with non-muscle-invasive bladder cancer (NMIBC) is immunotherapy with intravesical Bacillus Calmette-Guérin (BCG), which activates…

Ashish M. Kamat, Joaquim Bellmunt, Matthew D. Galsky, Badrinath R. Konety, Donald L. Lamm, David Langham, Cheryl T. Lee, Matthew I. Milowsky, Michael A. O’Donnell, Peter H. O’Donnell, Daniel P. Petrylak, Padmanee Sharma, Eila C. Skinner, Guru Sonpavde, John A. Taylor III, Prasanth Abraham and Jonathan E. Rosenberg

RESEARCH ARTICLE

New Content Item
Agonist anti-GITR antibody significantly enhances the therapeutic efficacy of Listeria monocytogenes-based immunotherapy

Many of the immune inhibitory and costimulatory receptors or their ligands are expressed on both immune suppressive cells such as regulatory…

Rajeev Shrimali, Shamim Ahmad, Zuzana Berrong, Grigori Okoev, Adelaida Matevosyan, Ghazaleh Shoja E. Razavi, Robert Petit, Seema Gupta, Mikayel Mkrtichyan and Samir N. Khleif

RESEARCH ARTICLE

New Content Item
Multi-target chimaeric VLP as a therapeutic vaccine in a model of colorectal cancer

Colorectal cancer is responsible for almost 700,000 deaths annually worldwide. Therapeutic vaccination is a promising alternative to conventional treatment for colorectal…

Braeden Donaldson, Farah Al-Barwani, Simon J. Pelham, Katie Young, Vernon K. Ward and Sarah L. Young

RESEARCH ARTICLE

New Content Item
The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment

T-cell checkpoint blockade and MEK inhibitor combinations are under clinical investigation. Despite progress elucidating the immuno-modulatory effects of MEK inhibitors as…

Edmund Poon, Stefanie Mullins, Amanda Watkins, Geoffrey S. Williams, Jens-Oliver Koopmann, Gianfranco Di Genova, Marie Cumberbatch, Margaret Veldman-Jones, Shaun E. Grosskurth, Vasu Sah, Alwin Schuller, Corrine Reimer, Simon J. Dovedi, Paul D. Smith, Ross Stewart and Robert W. Wilkinson

RESEARCH ARTICLE

New Content Item
Tumor-derived exosomes induce CD8+ T cell suppressors

The suppressive nature of immune cells in the tumor microenvironment plays a major role in regulating anti-tumor immune responses. Our previous...

Brian T. Maybruck, Lukas W. Pfannenstiel, Marcela Diaz-Montero and Brian R. Gastman

RESEARCH ARTICLE

New Content Item
Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab

Tremelimumab is an antibody that blocks CTLA-4 and demonstrates clinical efficacy in a subset of advanced melanoma patients. An unmet clinical…

Philip Friedlander, Karl Wassmann, Alan M. Christenfeld, David Fisher, Chrisann Kyi, John M. Kirkwood, Nina Bhardwaj and William K. Oh

 

View all articles

Aims and scope

Journal for ImmunoTherapy of Cancer (JITC) is an open access, peer reviewed journal that encompasses all aspects of tumor immunology and cancer immunotherapy, from basic research through to clinical applications.

JITC welcomes submissions to the following sections:

Society affiliation

Free Publication for Society Members

As a way to say thank you to the dedicated Society for Immunotherapy of Cancer (SITC) members who tirelessly work to advance the science and ultimately to improve the lives of patients with cancer, the Society is pleased to offer its members waived article processing charges for manuscripts accepted in JITC through 2016.

JITC Best Paper Awards

Awards were presented during SITC’s 31st Annual Meeting to the first authors of two JITC articles, representing the Best Clinical/Translational and Best Basic Science Papers published in JITC. Congratulations to Zipei Feng, Sachin Puri, and Katherine Woods!

For more information please email info@sitcancer.org, call +1 414 271-2456, or visit http://sitcancer.org/journal.

About SITC

The Society for Immunotherapy of Cancer (SITC) is a 501 (c)(3) non-profit society of medical professionals that was established in 1984 to exchange, encourage and promote information about the promise and breakthroughs of biological therapies, including immunotherapy, for patients with cancer. SITC is the world's leading member-driven society of medical professionals dedicated to advancing cancer immunotherapy through its initiatives, educational sessions, and collaborative endeavors. The Society has become the forum for innovative discussions in the field.

Society members include nearly 1000 influential leaders and scientists engaged in tumor immunology and cancer immunotherapy, including academicians, senior researchers, clinicians, students, government representatives, and industry leaders from around the world. SITC's members represent 17 medical specialties and are engaged in research and treatment of at least a dozen types of cancer.

SITC Mission

It is the mission of the Society for Immunotherapy of Cancer to improve cancer patient outcomes by advancing the science, development and application of immunotherapy through our core values of interaction/integration, innovation, translation and leadership in the field. SITC aims to make cancer immunotherapy a standard of care and the word “cure” a reality for cancer patients everywhere.

Advertisement

JITC logo

Advertisement